MA53124A - Agents de dégradation sélectifs des récepteurs des oestrogènes - Google Patents

Agents de dégradation sélectifs des récepteurs des oestrogènes

Info

Publication number
MA53124A
MA53124A MA053124A MA53124A MA53124A MA 53124 A MA53124 A MA 53124A MA 053124 A MA053124 A MA 053124A MA 53124 A MA53124 A MA 53124A MA 53124 A MA53124 A MA 53124A
Authority
MA
Morocco
Prior art keywords
eestrogen
receptor
selective degradation
degradation agents
agents
Prior art date
Application number
MA053124A
Other languages
English (en)
Other versions
MA53124B1 (fr
Inventor
Jolie Anne Bastian
Jeffrey Daniel Cohen
Almudena Rubio
Daniel Jon Sall
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53124(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA53124A publication Critical patent/MA53124A/fr
Publication of MA53124B1 publication Critical patent/MA53124B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Finger-Pressure Massage (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
MA53124A 2018-07-12 2019-07-11 Agents de dégradation sélectifs des récepteurs des oestrogènes MA53124B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12
PCT/US2019/041334 WO2020014435A1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs des récepteurs des oestrogènes

Publications (2)

Publication Number Publication Date
MA53124A true MA53124A (fr) 2021-05-19
MA53124B1 MA53124B1 (fr) 2023-02-28

Family

ID=67470734

Family Applications (2)

Application Number Title Priority Date Filing Date
MA53126A MA53126B1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs du récepteur des oestrogènes
MA53124A MA53124B1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs des récepteurs des oestrogènes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA53126A MA53126B1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs du récepteur des oestrogènes

Country Status (40)

Country Link
US (4) US10654866B2 (fr)
EP (2) EP3820873B1 (fr)
JP (6) JP6995241B2 (fr)
KR (3) KR102589886B1 (fr)
CN (2) CN112638916B (fr)
AR (3) AR115694A1 (fr)
AU (2) AU2019299947B2 (fr)
BR (1) BR122023025061A2 (fr)
CA (1) CA3105501C (fr)
CL (1) CL2021000045A1 (fr)
CO (1) CO2021000043A2 (fr)
CR (1) CR20210007A (fr)
DK (1) DK3820873T3 (fr)
EA (1) EA202092975A1 (fr)
EC (1) ECSP21001770A (fr)
ES (1) ES2933980T3 (fr)
FI (2) FI3820873T3 (fr)
FR (1) FR26C1020I1 (fr)
HR (1) HRP20230009T1 (fr)
HU (1) HUE060963T2 (fr)
IL (3) IL289871B2 (fr)
JO (1) JOP20210005B1 (fr)
LT (2) LT3820873T (fr)
MA (2) MA53126B1 (fr)
MD (1) MD3820873T2 (fr)
MX (2) MX2021000375A (fr)
MY (1) MY198962A (fr)
NL (1) NL301383I2 (fr)
NO (1) NO2026021I1 (fr)
PE (1) PE20210400A1 (fr)
PH (1) PH12021550049A1 (fr)
PL (1) PL3820873T3 (fr)
PT (1) PT3820873T (fr)
RS (1) RS63809B1 (fr)
SA (1) SA521421008B1 (fr)
SG (1) SG11202100148TA (fr)
SI (1) SI3820873T1 (fr)
TW (1) TWI702219B (fr)
UA (1) UA127507C2 (fr)
WO (1) WO2020014435A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059139A1 (fr) 2015-10-01 2017-04-06 Olema Pharmaceuticals, Inc. Médicaments anti-œstrogéniques de type tétrahydro-1h-pyrido[3,4-b]indole
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
MD3820874T2 (ro) * 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
CA3144791A1 (fr) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimes d'antagonistes du recepteur des oestrogenes
WO2021063967A1 (fr) 2019-10-01 2021-04-08 Sanofi Nouveaux composés 6,7-dihydro-5h-benzo[7]annulène substitués, procédés permettant leur préparation et leurs utilisations thérapeutiques
CA3160897A1 (fr) 2019-12-09 2021-06-17 Sanofi Forme cristalline d'un derive d'acide 7h-benzo[7]annulene-2-carboxylique
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
IL302153B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302152B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
WO2022106711A1 (fr) * 2020-11-23 2022-05-27 Sanofi Combinaison comprenant de l'abémaciclib et de l'acide 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphényl]-8,9-dihydro-7h-benzo[7]annulène-2-carboxylique
JP7846700B2 (ja) * 2021-02-16 2026-04-15 ジェネンテック， インコーポレイテッド Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
CN114957114A (zh) * 2021-02-26 2022-08-30 冷志 一种4-溴-3-氯-7-甲氧基喹啉的合成方法
TWI837605B (zh) 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
CN117042771A (zh) * 2021-03-09 2023-11-10 伊莱利利公司 使用serd给药方案的组合治疗癌症的方法
TWI894443B (zh) * 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
US20240199629A1 (en) * 2022-02-01 2024-06-20 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders
PE20241731A1 (es) * 2022-02-01 2024-08-19 Lilly Co Eli Procesos para la preparacion de degradadores selectivos del receptor de estrogeno
WO2024083716A1 (fr) 2022-10-17 2024-04-25 Astrazeneca Ab Combinaisons d'un serd pour le traitement du cancer
AU2023373671A1 (en) 2022-11-02 2025-05-15 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
JP2025539034A (ja) 2022-11-11 2025-12-03 アストラゼネカ・アクチエボラーグ 癌の治療のための併用療法
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer
WO2024233256A1 (fr) 2023-05-05 2024-11-14 Eli Lilly And Company Imlunestrant ou sels de celui-ci destinés à être utilisés dans le traitement et la prévention de métastases du système nerveux central (snc) chez des sujets ayant un cancer du sein er+
JP2026515235A (ja) 2023-05-11 2026-05-14 アストラゼネカ・アクチエボラーグ 癌を治療するためのｐａｒｐ１阻害剤と選択的エストロゲン分解薬の併用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
EP1395563B1 (fr) * 2001-05-22 2006-03-29 Eli Lilly And Company 1,2,3,4-tetrahydroquinoline 2-substituees et leurs derives, ainsi que leurs composition et leurs procedes
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
CA2480800C (fr) * 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibiteurs de l'activite akt
CA2482986A1 (fr) * 2002-04-19 2003-10-30 Signal Pharmaceuticals, Inc. Composes benzopyranone, compositions contenant ces composes et methodes de traitement associees
EA012262B1 (ru) * 2004-01-22 2009-08-28 Эли Лилли Энд Компани Селективные модуляторы рецепторов эстрогена для лечения вазомоторных симптомов
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
BR112015030595A2 (pt) * 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
WO2016097071A1 (fr) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Modulateurs du récepteur des œstrogènes et leurs utilisations
WO2017127442A1 (fr) * 2016-01-18 2017-07-27 The Regents Of The University Of California Méthodes de traitement du cancer à l'aide d'inhibiteurs ror gamma
TW201803870A (zh) * 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
WO2018108954A1 (fr) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Procédé de préparation de 2-(3-(fluorométhyl)azétidin-1-yl)éthan-1-ol
MD3820874T2 (ro) * 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
AR134662A2 (es) 2026-03-04
US20230234960A1 (en) 2023-07-27
SI3820873T1 (sl) 2023-02-28
IL295598A (en) 2022-10-01
CA3105501A1 (fr) 2020-01-16
JP2022037102A (ja) 2022-03-08
TWI702219B (zh) 2020-08-21
KR20230005404A (ko) 2023-01-09
LTPA2026519I1 (fr) 2026-05-25
EP3820873B1 (fr) 2022-11-23
CL2021000045A1 (es) 2021-07-19
KR102589886B1 (ko) 2023-10-17
AU2022203969A1 (en) 2022-06-30
MX2021000375A (es) 2021-05-27
IL280065A (en) 2021-03-01
ECSP21001770A (es) 2021-02-26
DK3820873T3 (da) 2022-12-12
KR102550538B1 (ko) 2023-07-04
IL289871B (en) 2022-10-01
AR115694A1 (es) 2021-02-17
BR122023025061A2 (pt) 2024-02-20
CR20210007A (es) 2021-02-08
PH12021550049A1 (en) 2021-09-20
HRP20230009T1 (hr) 2023-02-17
AR134487A2 (es) 2026-01-21
JP7746496B2 (ja) 2025-09-30
JOP20210005A1 (ar) 2021-01-10
US20210403480A1 (en) 2021-12-30
FI3820873T3 (fi) 2023-03-02
IL295598B2 (en) 2023-09-01
MA53126A (fr) 2021-05-19
MD3820873T2 (ro) 2023-05-31
FR26C1020I1 (fr) 2026-06-12
US10654866B2 (en) 2020-05-19
PT3820873T (pt) 2022-12-23
CA3105501C (fr) 2023-10-31
JP2022050591A (ja) 2022-03-30
JOP20210005B1 (ar) 2023-03-28
TW202019935A (zh) 2020-06-01
CO2021000043A2 (es) 2021-01-18
US20200017516A1 (en) 2020-01-16
JP2023081954A (ja) 2023-06-13
US20200347073A1 (en) 2020-11-05
FIC20260010I1 (fi) 2026-04-07
EA202092975A1 (ru) 2021-04-14
KR102783756B1 (ko) 2025-03-21
CN112638916A (zh) 2021-04-09
ES2933980T3 (es) 2023-02-15
JP2024169490A (ja) 2024-12-05
JP7009672B1 (ja) 2022-01-25
JP7241211B2 (ja) 2023-03-16
NO2026021I1 (no) 2026-04-21
JP6995241B2 (ja) 2022-01-14
KR20230148386A (ko) 2023-10-24
UA127507C2 (uk) 2023-09-13
EP3820873A1 (fr) 2021-05-19
AU2019299947A1 (en) 2021-01-07
CN117379428A (zh) 2024-01-12
EP4155310A1 (fr) 2023-03-29
PE20210400A1 (es) 2021-03-02
NL301383I2 (nl) 2026-05-22
JP2025186400A (ja) 2025-12-23
SG11202100148TA (en) 2021-02-25
IL289871A (en) 2022-03-01
JP7557564B2 (ja) 2024-09-27
AU2022203969B2 (en) 2024-02-15
NZ771718A (en) 2024-05-31
US11634426B2 (en) 2023-04-25
KR20210019065A (ko) 2021-02-19
IL289871B2 (en) 2023-02-01
IL295598B1 (en) 2023-05-01
IL280065B (en) 2022-04-01
HUE060963T2 (hu) 2023-04-28
US11117902B2 (en) 2021-09-14
MA53126B1 (fr) 2023-02-28
AU2019299947B2 (en) 2022-03-17
LT3820873T (lt) 2023-01-10
JP2021530484A (ja) 2021-11-11
CN112638916B (zh) 2023-09-12
MY198962A (en) 2023-10-05
SA521421008B1 (ar) 2022-10-30
BR112020025654A2 (pt) 2021-04-06
MX2023006047A (es) 2023-06-02
US11993608B2 (en) 2024-05-28
WO2020014435A1 (fr) 2020-01-16
PL3820873T3 (pl) 2023-02-13
MA53124B1 (fr) 2023-02-28
RS63809B1 (sr) 2023-01-31

Similar Documents

Publication Publication Date Title
MA53126A (fr) Agents de dégradation sélectifs du récepteur des oestrogènes
EP3897631A4 (fr) Dégradation ciblée de protéines
EP3860183A4 (fr) Dispositif de relais
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
IL268824A (en) Improved antigen binding receptor formats
DK3762380T3 (da) Phenylpyrrolidinon-formylpeptid-2-receptoragonister
PL3660004T3 (pl) Związki i sposoby do ukierunkowanej degradacji receptora androgenowego
ES1243880Y (es) Cepillo de dientes
EP3521427A4 (fr) Co-récepteur de récepteur odorant
EP3876986A4 (fr) Immunotolérance ciblée
EP3801134A4 (fr) Agencement de siège
EP3763567A4 (fr) Siège
DE112020001082A5 (de) Löschvorrichtung
PL3820874T3 (pl) Selektywne środki degradujące receptor estrogenowy
MA52555A (fr) Modulateurs du récepteur des oestrogènes
EP3899155A4 (fr) Raccord amélioré
DK3412840T3 (da) Toilet
EP3848096A4 (fr) Extincteur
EP3772318C0 (fr) Hystéroscope
MA53666A (fr) Purification de stérol
EP3790528A4 (fr) Composition de désinfectant sous forme de mousse
DK3649043T3 (da) Flugtsystem
EP3816357C0 (fr) Dispositif de toilettes
DK3621871T3 (da) Flugtsystem
EP3854794A4 (fr) Agoniste de tlr8